Is Immuneering Corp (IMRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 10.5% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.2% / 33% | 10.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 7.9% / 33% | 68.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 10.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 7.9% / 33% | 68.6% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -43.1% | |
| Return on Assets (ROA) | -26.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$45M |
| Free Cash Flow | -$45M |
| Total Debt | $4M |
| Debt-to-Equity | 1.8 |
| Current Ratio | 17.5 |
| Total Assets | $232M |
Price & Trading
| Last Close | $5.22 |
| 50-Day MA | $5.04 |
| 200-Day MA | $5.40 |
| Avg Volume | 1.7M |
| Beta | 0.5 |
|
52-Week Range
$1.10
| |
About Immuneering Corp (IMRX)
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Immuneering Corp (IMRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Immuneering Corp is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Immuneering Corp's debt ratio?
Immuneering Corp's debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.9%.
What are Immuneering Corp's key financial metrics?
Immuneering Corp has a market capitalization of $321M. Return on equity stands at -43.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.